Bosentan

Chemical formula: C₂₇H₂₉N₅O₆S  Molecular mass: 551.614 g/mol  PubChem compound: 104865

Therapeutic indications

Bosentan is indicated for:

Pulmonary arterial hypertension (PAH)

Population group: only adults (18 years old or older)

Bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

  • Primary (idiopathic and heritable) PAH
  • PAH secondary to scleroderma without significant interstitial pulmonary disease
  • PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology

Some improvements have also been shown in patients with PAH WHO functional class II.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Systemic sclerosis

Population group: only adults (18 years old or older)

Bosentan is indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Bosentan is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Ciclosporine A

Ciclosporin

Moderate hepatic impairment, severe hepatic impairment

at least one of
Hepatic failure stage III
Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: TRACLEER Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈